União Europeia - português - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - doença de fabry - outro aparelho digestivo e metabolismo produtos, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).